Listing a study does not mean it has been evaluated by the U. The epidermal growth factor receptor (EGFR) signaling pathway plays a central role in the neoplastic transformation of NSCLC and promotes cancer cell survival, metastasis, and angiogenesis. Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality in men and women in Singapore. Chloroquine resistant areas Has there been a plaquenil class action lawsuit Lose weight after plaquenil Skin splits on fingertips hydroxychloroquine Hydroxychloroquine and Gefitinib to Treat Lung Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U. S. Federal Government. Home About cancer Find a clinical trial A trial of chemotherapy and hydroxychloroquine for small cell lung cancer STUDY 15 A trial of chemotherapy and hydroxychloroquine for small cell lung cancer STUDY 15 This trial is looking at adding hydroxychloroquine to chemotherapy for people with small cell lung cancer that has spread. Lung cancer that has spread is called advanced lung cancer. Over the last three years, the FDA has approved two drugs for salvage treatment of NSCLC, gefitinib (Iressa ®, formerly known as ZD1839) and erlotinib (Tarceva ®, formerly known as OSI-774). The predominance of EGFR signaling in NSCLC makes the pathway an attractive candidate for the development of targeted therapeutics. Hydroxychloroquine lung cancer Hydroxychloroquine induced lung cancer suppression by., A trial of chemotherapy and hydroxychloroquine for small cell. Hydroxychloroquine sulfate 200 mg patient information leafletPlaquenil and lexapro interactionsPlaquenil while taking maltacPlaquenil side effects eye tests Studies in genetically engineered mouse models demonstrate that autophagy inhibition suppresses lung tumor development and progression, especially in Kras mutated tumors. We report safety and efficacy of adding an autophagy inhibitor, hydroxychloroquine HCQ to front-line platinum-based chemotherapy in a phase Ib single arm study in patients with metastatic NSCLC. Modulation of autophagy with hydroxychloroquine in.. A trial of chemotherapy and hydroxychloroquine for small.. Management Considerations in Cancer Patients With.. Cancer plus an additional drug, hydroxychloroquine. The standard treatment for lung cancer. being used includes 2 chemotherapy drugs, called paclitaxel and carboplatin, plus a drug. that targets blood vessels, called bevacizumab also known as avastin. Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous. Researchers in the laboratory have tested tumors from patients with pancreatic cancer and have discovered that they have certain pathways inside the cells that promote growth and survival of the tumor. Non–small-cell lung cancer NSCLC is the most common cause of cancer mortality in the United States 1 and chemotherapy is only modestly effective.